03 Jun Roche NimbleGen partners with California bioinformatics firm
Madison, Wis. – Roche NimbleGen Inc., a subsidiary of Roche Applied Science, has announced a strategic alliance with the California-based BioDiscovery to offer scientists a more complete product solution for genomic data analysis.
The two companies will combine a high-density array, or slide, developed by Roche NimbleGen with proprietary software developed by BioDiscovery, and jointly market the product worldwide.
According to Dr. Soheil Shams, president of BioDiscovery, the combined technologies will enable scientists to analyze data from millions of probes across thousands of samples.
Through a series of seminars, they also plan to present data generated by the new product to the research community.
Roche NimbleGen is the product of the 2007 acquisition of Madison’s NimbleGen by Roche, the pharmaceutical and diagnostic corporation headquartered in Basel, Switzerland.
BioDiscovery, founded in Los Angeles in 1997, develops microarray bioinformatics software and services.
• Entrepreneurial lessons: NimbleGen did not set out to be an acquisition target
• Tom Still: Reykjavik connection: How teamwork produced a stem cell breakthrough
• NimbleGen to discontinue IPO after Roche’s $272.5 million acquisition
• IPO-bound NimbleGen traveling in fast company
• Madison biotech NimbleGen files for IPO; one of states’ best-funded firms
• Genomics researcher Hood joins NimbleGen board